Global Custom Antibody (mAbs, pAbs, rAbs) Market Research 2024-2030: Service (Development, Purification, Fragmentation, Labeling), Source (Rabbit, Mice), Application (Research, Therapeutics)
June 19, 2024 10:01 ET
|
Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Global Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice),...
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
June 03, 2024 07:00 ET
|
Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
May 06, 2024 08:00 ET
|
Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
April 25, 2024 05:00 ET
|
PEP-Therapy
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patientsdans la phase Ib de l’essai clinique évaluant PEP-010dans les cancers de l’ovaire et du pancréas ...
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
April 25, 2024 05:00 ET
|
PEP-Therapy
Press release PEP-Therapy and Institut Curie Announce First Patients Dosedin Phase Ib Clinical Trial Evaluating PEP-010in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy,...
Peptide Therapeutics Analysis Report 2024 - Global Forecast to 2030 Featuring Eli Lilly and Co, Pfizer, Amgen, Takeda, AstraZeneca, Teva, Sanofi, F. Hoffmann-La Roche, Novartis, Novo Nordisk
April 22, 2024 04:14 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 03, 2024 06:30 ET
|
Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
December 21, 2023 21:16 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to...
Peptide Therapeutics Market Set to Surpass USD 80 Billion by 2029: In-Depth Analysis of Global Trends and Clinical Trials
December 06, 2023 03:48 ET
|
Research and Markets
Dublin, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering....